Cited by 406Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

Open access

Buzdar, A, Jonat, W, Howell, A, Jones, S E, Blomqvist, C, Vogel, C L, Eiermann, W, Wolter, J M, Azab, M, Webster, A, Plourde, P V·1996·Journal of Clinical Oncology

DOI 10.1200/jco.1996.14.7.2000

Open this paper in CoChat — free account

Abstract

PURPOSE: To compare the efficacy and tolerability of anastrozole (1 and 10 mg once daily), a selective, oral, nonsteroidal aromatase inhibitor, and megestrol acetate (40 mg four times daily), in postmenopausal women who progressed following tamoxifen treatment. PATIENTS AND METHODS: Two randomized, double-blind for anastrozole, open-label for megestrol acetate, parallel-group, multicenter trials were conducted in 764 patients. Because both trials were identical in design, an analysis of the combined results was performed to strengthen interpretation of results from each trial. RESULTS: The median follow-up duration was approximately 6 months. The estimated progression hazards ratios were 0.97 (97.5% confidence interval [CI], 0.75 to 1.24) for anastrozole 1 mg versus megestrol acetate and 0.92 (97.5% CI, 0.71 to 1.19) for anastrozole 10 mg versus megestrol acetate. The overall median time to progression was approximately 21 weeks. Approximately one third of patients in each group benefited from treatment. Twenty-seven patients (10.3%) in the anastrozole 1-mg group, 22 (8.9%) in the anastrozole 10-mg group, and 20 (7.9%) in the megestrol acetate group had a complete or partial response, and 66 (25.1%), 56 (22.6%), and 66 (26.1%) patients, respectively, had stable disease for > or = 24 weeks. For all end points, individual trial results were similar to the results of the combined analysis. Anastrozole and megestrol acetate were well tolerated. Gastrointestinal disturbance was more common among patients in the anastrozole groups than the megestrol acetate group; the difference between the anastrozole 10 mg and megestrol acetate groups was significant (P = .005). Significantly fewer patients in the anastrozole 1-mg (P < .0001) and 10-mg (P < .002) groups had weight gain than in the megestrol acetate group. More than 30% of megestrol acetate-treated patients had weight gain > or = 5%, and 10% of patients had weight gain > or = 10%. Patients who received megestrol acetate continued to gain weight over time. CONCLUSION: Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment. Moreover, anastrozole therapy avoids the weight gain associated with megestrol acetate treatment.

Integrity signals

Registry

Crossref · 10.1200/jco.1996.14.7.2000

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist
de Haes, J., van Knippenberg, F. C. E., & Neijt, J. P. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.434 · Cited by 907
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., KUMAOKA, S., SEGALOFF, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 715
Tamoxifen in advanced breast cancer
Mouridsen, H. T., Palshof, T., Patterson, J., & Battersby, L. (1978) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(78)80017-6 · Cited by 333
Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia
Loprinzi, C. L., Ellison, N. M., Schaid, D. J., Krook, J. E., Athmann, L. M., Dose, A. M., Mailliard, J. A., Johnson, P. S., Ebbert, L. P., & Geeraerts, L. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1127 · Cited by 318
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heuson, J.-C., KUMAOKA, S., SEGALOFF, A., & Rubens, R. D. (1977) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(77)90234-1 · Cited by 310
Arimidex�: A potent and selective fourth-generation aromatase inhibitor
Plourde, P. V., Dyroff, M. C., & Dukes, M. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682745 · Cited by 258
Experimental and clinical results with intraperitoneal cisplatin.
Huinink, W. W. T. B., Dubbelman, R., Aartsen, E. J., Franklin, H. L., & Jg, M. (1985) · PubMed · Cited by 148
The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
Howell, A., Mackintosh, J., Jones, M., Redford, J., Wagstaff, J., & Sellwood, R. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90046-6 · Cited by 106
Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer
Ingle, J. N., Ahmann, D. L., Green, S., Edmonson, J. H., Creagan, E. T., Hahn, R. G., & Rubin, J. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198204000-00062 · Cited by 73

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 301–400 of 406

Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer?
Kolben, T., Bardenhewer, M., Kolben, T. M., Rickerl, L., Degenhardt, T., Mahner, S., Harbeck, N., & Wuerstlein, R. (2019) · Breast Care · doi:10.1159/000504527 · Cited by 3
Systemic Therapy of Bone Metastases
Kamposioras, K. V., & Briasoulis, E. C. (2013) · Cancer metastasis · doi:10.1007/978-94-007-7569-5_13 · Cited by 3
Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?
Howell, A. (2005) · Women s Health · doi:10.2217/17455057.1.3.309 · Cited by 3
Long-Term Survival of Women with Locally Advanced Breast Cancer with ≥10 Involved Lymph Nodes at Diagnosis
Zeichner, S. B., Cavalcante, L. L., Suciu, G., Ruiz, A. L., Hirzel, A. C., & Krill-Jackson, E. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.8.3435 · Cited by 3
Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: guideline recommendations
Flemming, J. A., Madarnas, Y., & Franek, J. A. (2008) · Cited by 3
Current role of endocrine therapy in the management of breast cancer
Robertson, J. F. R. (2002) · Breast Cancer · doi:10.1007/bf02967604 · Cited by 3
Aromatase inhibitors and breast cancer: time for a change?
Fentiman, I. S. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2004.00363.x · Cited by 3
Fortschritte in der Hormontherapie des Mammakarzinoms
Brodowicz, T., Wiltschke, C., & Zielinski, C. (1998) · Oncology Research and Treatment · doi:10.1159/000026866 · Cited by 3
Results of phase II and phase III trials with new aromatase inhibitors
Jonat, W. (1996) · The Breast · doi:10.1016/s0960-9776(96)90095-8 · Cited by 3
Aromatase inhibitors for breast cancer: pharmacoeconomic considerations
Higa, G. M. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.6.987 · Cited by 3
Systemische Therapie des metastasierten Mammakarzinoms
Möbus, V. J., & Kreienberg, R. (2002) · Springer eBooks · doi:10.1007/978-3-662-08460-1_19 · Cited by 3
Endocrine Therapy for Breast Cancer
Pinder, M. C., & Buzdar, A. U. (2007) · Springer eBooks · doi:10.1007/978-0-387-34952-7_14 · Cited by 2
Quantitative Structure–Activity Relationship for Inhibition of CYP2B6 and CYP3A4 by Azole Compounds – Comparison with Their Binding Affinity
Itokawa, D., Yamauchi, A., & Chuman, H. (2009) · QSAR & Combinatorial Science · doi:10.1002/qsar.200730115 · Cited by 2
Aromatase Inhibitors in Breast Carcinoma
Harvey, H. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-699-7_16 · Cited by 2
Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer
Liedtke, C., & Kolberg, H. (2015) · Visceral Medicine · doi:10.1159/000441961 · Cited by 2
Recent advances in the systemic therapy of breast cancer.
COLE, J. T. (2000) · PubMed Central · Cited by 1
Endokrine Therapie des metastasierten Mammakarzinoms
Loibl, S., von Minckwitz, G., & Kaufmann, M. (2003) · Der Gynäkologe · doi:10.1007/s00129-002-1323-0 · Cited by 1
The third-generation aromatase inhibitors: a clinical overview
Buzdar, A. U. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8693-1_7 · Cited by 1
Sex Steroid Production from Cryopreserved and Reimplanted Ovarian Tissue
Lee, S., & Ku, S. (2012) · InTech eBooks · doi:10.5772/53098 · Cited by 1
Treatment Options For Postmenopausal Women with Tamoxifen-Resistant Advanced Breast Cancer
Cheung, K., & Robertson, J. F. R. (2002) · American Journal of Cancer · doi:10.2165/00024669-200201040-00006 · Cited by 1
InforMatrix Aromatase Inhibitors in Breastcancer
Janknegt, R. (2016) · Journal of Pharmaceutical Care & Health Systems · doi:10.4172/2376-0419.1000111 · Cited by 1
Patterns in target-directed breast cancer research
Torres, S., Simmons, C. E., Boileau, J.-F., McLeod, D., Martins, I., & Trudeau, M. (2016) · SpringerPlus · doi:10.1186/s40064-016-1736-1 · Cited by 1
The third-generation aromatase inhibitors: a clinical overview
Buzdar, A. U. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7418-7_7 · Cited by 1
Photoredox-Catalyzed Decarboxylative Cross-Coupling Reaction to Synthesis Unsymmetrical Diarylmethanes
Guo, G., Zhang, Y., Li, Y., & Li, Z. J. (2024) · Molecules · doi:10.3390/molecules29092156 · Cited by 1
Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research
Sokolowicz, L. E., & Gradishar, W. J. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0023-z · Cited by 1
Management of Advanced Breast Cancer in Young Women: What’s New in Systemic Treatment
Volovăț, S. R., Ribeiro, J. M., Konsoulova, A., Paluch–Shimon, S., & Cardoso, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-24762-1_12 · Cited by 1
Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing
Çılbır, E., & Yalçın, Ş. (2019) · Springer eBooks · doi:10.1007/978-3-030-04606-4_10 · Cited by 1
Stratégies thérapeutiques des cancers du sein métastatiques : RH+ HER2−. Hormonothérapies, chimiothérapies (monochimiothérapies séquentielles ou polychimiothérapies concomitantes ?), antiangiogéniques
Debled, M., & Mauriac, L. (2010) · Springer eBooks · doi:10.1007/978-2-8178-0076-9_20 · Cited by 1
Aromatase Inhibitors and the Role of Hormonal Therapy in Breast Cancer
Herschler, K. E. D., & Brodie, A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-456-6_22 · Cited by 1
Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer
Grant, M., & Rea, D. W. (2004) · Therapy · doi:10.1586/14750708.1.2.305 · Cited by 1
Aromatase inhibitors for breast cancer—further progress
Rubens, R. D. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00106-8 · Cited by 1
Cáncer de mama. tratamiento
Villaverde, R. M., González, J. L. L., & Barón, M. G. (2001) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(01)70569-0 · Cited by 1
Aromatase inhibitors in the early adjuvant setting – the latest evidence
Mouridsen, H. T. (2006) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2006.06.001 · Cited by 1
Management of Advanced Breast Cancer: Defining the Role of Toremifene
Holliday, S. M., & Faulds, D. M. (1998) · Disease Management & Health Outcomes · doi:10.2165/00115677-199803030-00004 · Cited by 1
The endocrine management of postmenopausal women with early breast cancer
Baum, M. (2004) · Breast Cancer · doi:10.1007/bf02967995 · Cited by 1
Postmenopausal Metastatic Breast Cancer
Assersohn, L., & Johnston, S. R. D. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302020-00003 · Cited by 1
Resistance to Antiestrogens
Osipo, C., & O'Regan, R. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-035-5_22 · Cited by 1
Irreversible aromatase inactivation: treatment for breast cancer
Johnston, S. R. D. (2000) · Hospital Medicine · doi:10.12968/hosp.2000.61.9.1424 · Cited by 1
Breast Cancer: Side Effects of Tamoxifen and Anastrozole
Benson, J. R., Turner, E. H., & Winters, Z. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8369-3_31 · Cited by 1
Inhibitory actions of Ah receptor agonists and indole-containing compounds in breast cancer cell lines and mouse models
Walker, K. (2005) · OakTrust (Texas A&M University Libraries) · Cited by 1
State of the Art der endokrinen Therapie des metastasierten Mammakarzinoms
Kolberg, H.-C., Löning, M., Diesing, D., Friedrich, M., & Diedrich, K. (2005) · Gynäkologische Endokrinologie · doi:10.1007/s10304-005-0103-z · Cited by 1
Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer
Buzdar, A. U., Dawood, S. S., Harvey, H. A., & Jordan, V. C. (2019) · Wiley eBooks · doi:10.1002/9781119000822.hfcm062.pub2 · Cited by 1
Novel Aromatase Inhibitors
Sharma, R., Chopra, V., & Sharma, C. (2009) · Cited by 1
Aromatase Inhibitors
Goss, P. E., & Reid, C. (2009) · Humana Press eBooks · doi:10.1007/978-1-59259-152-7_11 · Cited by 1
Hormonal Therapy
Tubiana-Hulin, M., & Soulié, P. (2002) · Springer eBooks · doi:10.1007/978-1-4471-3251-6_6 · Cited by 1
Adjuvant Systemic Therapy for Breast Cancer: An Overview
Kaklamani, V., & Gradishar, W. J. (2010) · Springer eBooks · doi:10.1007/978-3-540-69743-5_17
Hormonal Therapy of Breast Cancer
Moore, H. C. F., & Fox, K. R. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-161-9_10
Do We Have Good Surrogate Endpoints for Survival in Breast Cancer Studies?
Lohrisch, C. A., & Piccart, M. J. (2000) · Tumori Journal · doi:10.1177/03008916000865s102
Clinical studies with anastrozole
Howell, A., & Wakeling, A. E. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8693-1_6
Mild forms of ovarian stimulation
Aboulghar, M. A., & Rizk, B. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511762390.004
An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
Gutteridge, E. (2010) · Nottingham ePrints (University of Nottingham)
Pulmonary thromboembolism in a breast cancer woman receiving anastrozole and prophylactic nadroparin
Molina-Garrido, M. J., & Guillén‐Ponce, C. (2007) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-007-0078-4
Changes in endocrine therapy: Anastrozole and advanced breast cancer in postmenopausal women
Nabholtz, J. (2004) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990910402100612
Place des inhibiteurs de l’aromatase dans le cancer du sein de la femme ménopausée, en situation adjuvante: les acquis et les incertitudes en 2005
Lesur, A., Cutuli, B., Teissier, M. P., & Luporsi, É. (2006) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/s0368-2315(06)76405-5
Current State of the Treatment in Metastatic Breast Cancer
Conte, P., & Bengala, C. (2006) · Journal of Breast Cancer · doi:10.4048/jbc.2006.9.1.4
Antiaromatase Agents: Evolving Role in Adjuvant Therapy
Jones, S. E. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.n.010
Implications of First-Line Adjuvant Treatment with Aromatase Inhibitors in Recurrent Metastatic Breast Cancer
Sokolowicz, L. E., & Gradishar, W. J. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.s.011
Anastrozole Versus Exemestane in Patients with Postmenopausal Breast Cancer and Visceral Metastases
Cancer, P. B., Metastases, V., Sachdev, J. C., Schreiber, A. M., & Jahanzeb, M. (2010) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s1564
c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients
Zilembo, N., Mariani, L., Martinetti, A., Miceli, R., Seregni, E. C., Bichisao, E., Torre, I. L., Pozzi, P., Ferrari, L., Candis, D. D., et al. (2002) · The Breast · doi:10.1054/brst.2002.0416
Does Switching from Tamoxifen to an Aromatase Inhibitor Result in Weight Change in Postmenopausal Breast Cancer Patients?~!2010-04-23~!2010-07-08~!2010-07-26~!
Makari‐Judson, G. (2010) · The Open Breast Cancer Journal · doi:10.2174/1876817201002010066
Case study from the Garvan Institute of Medical Research: long-term survival of a patient with metastatic breast cancer and hypercalcaemia
McNeil, C. M., & Grygiel, J. J. (2005) · Breast Cancer Online · doi:10.1017/s1470903105004141
Second-line treatment of postmenopausal women with advanced breast carcinoma
Ruth E Board, Dean, E. J., Mitchell, C. L., & Wardley, A. M. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.4.613
Present and Emerging Targeted Therapy for Metastatic Breast Cancer
Lorusso, V., Marech, I., Giampaglia, M., Tinelli, A., & Chiurì, V. E. (2012) · Journal of cancer research updates · doi:10.6000/1929-2279.2012.01.01.14
Does Switching from Tamoxifen to an Aromatase Inhibitor Result in Weight Change in Postmenopausal Breast Cancer Patients
Makari‐Judson, G., Capizzi, T. F., & Mertens, W. C. (2010) · The Open Breast Cancer Journal
Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer
Ligibel, J. A., & Winer, E. P. (2005) · Women s Health · doi:10.2217/17455057.2.1.89
Superior E fficacy o f L etrozole V ersus T amoxifen a s First-Line T herapy f or P ostmenopausal W omen W ith Advanced B reast C ancer: R esults o f a P hase I II S tudy o f the I nternational L etrozole B reast C ancer G roup
Mouridsen, H. T., Gershanovich, M., Sun, Y., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R. E., Sleeboom, H. P., Pluzanska, A., Dank, M., et al. (2001)
Invasive Breast CancerPractice Guidelines in Oncology
Smith, M. L., Somlo, G., Ward, J. H., Wolff, A. C., Zellars, R. C., Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., et al. (2011)
Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741
Abrams, J. S., Aisner, J., Cirrincione, C., Berry, D. A., Muss, H. B., Cooper, M. R., Craig, I. R., Panasci, L., Kirshner, J., Ellerton, J. A., et al. (1999)
Clinical Utility of Aromatase Inhibitors
Shenton, K., Dowsett, M., & Dukes, M. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-152-7_12
Hormonotherapy of Bone Metastases
Kamposioras, K. V., & Briasoulis, E. C. (2009) · Cancer metastasis · doi:10.1007/978-1-4020-9819-2_15
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Secretariat, A. (2002)
Investigation of the mechanisms of estrogen receptor activation by phosphorylation
Halliday, A. C. (2009) · Spiral (Imperial College London) · doi:10.25560/4348
Aromatase Inhibitors for Breast Cancer Treatment and Prevention
Mayer, E. L., & Winer, E. P. (2007) · Translational medicine series · doi:10.3109/9781420019940.014
Structural and Molecular Imaging in Cancer Therapy Clinical Trials
Kurland, B. F., & Mankoff, D. A. (2012) · Chapman & Hall/CRC eBooks · doi:10.1201/b11800-28
Endocrine therapy for advanced disease
Johnston, S. R. D. (2006) · CRC Press eBooks · doi:10.3109/9780203696910-4
ADVANCES WITH AROMATASE INHIBITORS
Chumsri, S., Bao, T., Sabnis, G. J., & Brodie, A. M. H. (2013) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781848169586_0009
Systemic hormonal therapies for early-stage breast cancer
Johnston, S. R. D. (2013) · CRC Press eBooks · doi:10.1201/b13937-45
Exemestane I s S uperior t o M egestrol A cetate A fter Tamoxifen F ailure i n P ostmenopausal W omen W ith Advanced B reast C ancer: R esults o f a P hase I II Randomized D ouble-Blind T rial
Kaufmann, M., Bajetta, E., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Červek, J., Fowst, C., et al. (2000)
Anastrozoleof its Use in the Management of Postmenopausal Women with Advanced Breast Cancer
Wiseman, L. R., & Adkins, J. (1998)
Neue Hormone und Zytostatika in der Tumortherapie
Thema, Z. (1997)
Aminoglutethimide and Megestrol
Solimando, D. A. (1999) · Hospital Pharmacy · doi:10.1177/001857879903400303
Comparative Effectiveness Research/Health Technology Assessment (HTA) Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
Cope, S. F., Jansen, J. P., & Schmid, P. (2013)
Hormone-blocking therapy: patient selection and clinical outcomes
Su, A. R., & Rimawi, M. F. (2013) · doi:10.2217/ebo.13.443
Endocrine Agents
Masterpol, K. S., Dickler, M. N., & Lacouture, M. E. (2013) · doi:10.1002/9781118590638.ch24
Synthesis of 3-(Piperidin-4-yl)-6,7-dihydro-5H-pyrrolo-[2,1-c][1,2,4]triazole and Theoretical Study of the Hydrazone-Hydrazine Tautomerism of the Intermediate Hydrazonation Product
Zhang, Q.-Z., Wan, C.-F., Ma, Y., Qin, N.-N., Ke, C., Pan, Q., & Zhang, X.-L. (2019) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428019080232
Reducing the risk of late recurrence in hormone-responsive breast cancer
ufer, T. C. Ÿ. (2007)
Therapy Regimens Used in Adjuvant and Neoadjuvant Treatment of the Discussed Tumor Types
Possinger, K., Schauer, A., Griesinger, F., & Roever, A. C. (2005) · Springer eBooks · doi:10.1007/3-540-26393-4_33
Onkologie ’96
Hartmann, F., & Pfreundschuh, M. G. (1997) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/bf03042290
Endocrine Therapy
Howell, S. J., & Howell, A. (2010) · Springer eBooks · doi:10.1007/978-3-540-69743-5_18
Oral Agents for Ovarian Stimulation
Mitwally, M. F., & Casper, R. F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781316477021.004
Reproductive Health LiteratureWatch
(1996) · Journal of Women s Health · doi:10.1089/jwh.1996.5.505
Breast Cancer
Liu, M., & Lippman, M. E. (2001) · doi:10.1007/978-1-4613-1099-0_6
Antiaromatasas
Pujol, P., & Bringer, J. (2001) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(01)71889-9
Endokrine Therapie des metastasierten Mammakarzinoms mit Arimidex
Hilfrich, J., & Ehmer, M. (1999) · De Gruyter eBooks · doi:10.1515/9783110810134.15
Clinical studies with anastrozole
Howell, A., & Wakeling, A. E. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7418-7_6
Endocrine therapy for advanced disease
Johnston, S. R. D. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848129.003
Sex hormones and related compounds, including hormonal contraceptives
Buitenhuis, A., & van Boxtel, C. J. (1998) · Side effects of drugs annual · doi:10.1016/s0378-6080(98)80044-5
Recent Developments in the Hormonal Treatment of Breast Cancer
Boeddinghaus, I., & Dowsett, M. (2002) · CRC Press eBooks · doi:10.1201/b14039-13
Cáncer de mama metastásico
Espié, M., Bonnet-Bensimon, C., de Castelbajac, V., Cuvier, C., Giacchetti, S., & Teixeira, L. (2022) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(22)46717-8
Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer
Buzdar, A. U., Dawood, S. S., Harvey, H. A., & Jordan, V. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm062

Authors: Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., & Plourde, P. V.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
ORCID: Buzdar, A
Howell, A
Jones, S E
Blomqvist, C
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1996-07
Volume: 14
Issue: 7
Pages: 2000-2011
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1996.14.7.2000
OpenAlex: W1909697168
Cited by: 406
References: 24
Citations by year: 2025: 2 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 8 · 2018: 2 · 2017: 5 · 2016: 11 · 2015: 7 · 2014: 4 · 2013: 18 · 2012: 10
FWCI: 12.96
Type: journal article
Language: en
Open access: green
research.manchester.ac.uk
Licence: other-oa
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Research Explorer (The University of Manchester) (publishedVersion, other-oa)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: anastrozole, megestrol acetate, aromatase inhibitors, advanced breast cancer, postmenopausal women, progression-free survival, time to progression, complete response, stable disease, gastrointestinal adverse effects, weight gain, drug tolerability, dose comparison, combination chemotherapy, combined radiotherapy, combination endocrine therapy
MeSH terms: Anastrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Double-Blind Method, Female, Humans, Megestrol, Middle Aged, Nitriles, Prognosis, Tamoxifen, Triazoles, Survival Rate, Postmenopause, Disease Progression, Antineoplastic Agents, Hormonal, Megestrol Acetate, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks